Actinium Pharmaceuticals, Inc. announced via press release on October 30, 2026, that it granted an inducement stock option to a newly hired non-executive employee on October 26, 2026, covering 3,000 shares of common stock at an exercise price of $1.40 per share.

Key Highlights

  • Grant date: October 26, 2026, with an exercise price of $1.40 per share, equal to the closing price of Actinium's common stock on NYSE American on that date.
  • Share count: The option covers 3,000 shares of the company's common stock.
  • Vesting schedule: 28% of shares vest on the first anniversary of the grant date; the remaining shares vest in equal monthly installments of 2% over the following 36 months.
  • Option term: The option has a ten-year term.
  • Plan basis: The award was granted outside of the company's Amended and Restated 2019 Stock Plan under Section 711(a) of the NYSE American Company Guide, as an inducement material to the employee's entry into employment.
  • Governing plan: The award is subject to the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan and the applicable award agreement.

Actinium Issues Inducement Option to New Non-Executive Hire

According to the announcement, Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) granted a non-qualified stock option to a newly hired non-executive employee on October 26, 2026. The option entitles the recipient to purchase 3,000 shares of the company's common stock at $1.40 per share, a price the company disclosed is equal to the closing price of Actinium's common stock on the NYSE American on the grant date.

The filing states that the option carries a ten-year term. Vesting is structured so that 28% of the shares vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments of 2% of the shares underlying the option over the subsequent 36 months. The company noted that vesting is subject to the employee's continued service through each applicable vesting date.

Actinium disclosed that the award was granted outside of its Amended and Restated 2019 Stock Plan. The company stated the grant was made "as an inducement material to the employee's entering into employment with the Company in accordance with Section 711(a) of the NYSE American Company Guide," and is governed by the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan and the applicable award agreement. The press release also contains forward-looking statements, which the company noted are subject to risks and uncertainties and are based on management's current expectations.

What Was Disclosed

Actinium Pharmaceuticals disclosed a non-qualified stock option grant of 3,000 shares at $1.40 per share to a newly hired non-executive employee, granted on October 26, 2026, outside the company's existing 2019 Stock Plan and under its 2026 Employment Inducement Award Plan.